Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.

The proteasome inhibitor bortezomib has shown impressive clinical activity alone and in combination with conventional and other novel agents for the treatment of multiple myeloma (MM). Although bortezomib is known to be a selective proteasome inhibitor, the downstream mechanisms of cytotoxicity and...

詳細記述

書誌詳細
主要な著者: Shringarpure, R, Catley, L, Bhole, D, Burger, R, Podar, K, Tai, Y, Kessler, B, Galardy, P, Ploegh, H, Tassone, P, Hideshima, T, Mitsiades, C, Munshi, N, Chauhan, D, Anderson, K
フォーマット: Journal article
言語:English
出版事項: 2006